Home > Press > Intertek Acquires QTI Laboratory
Intertek Group plc (Intertek), a leading international provider of quality and safety services to a wide range of industries, has acquired Quantitative Technologies Inc. (QTI). QTI will operate in the Intertek OCA Division (Caleb Brett) Pharmaceutical Services group.
Intertek Acquires QTI Laboratory
HOUSTON, TX & LONDON, UK | Posted on June 7th, 2007
QTI is a leading contract analytical research and development laboratory that has been serving the pharmaceutical, medical device and drug delivery industry in North America for over 15 years, specialising in the pre-market launch stages of the drug and product development life cycle. QTI is located in Whitehouse, New Jersey with approximately 60 staff and counts major global pharmaceutical companies among its clients. The laboratory is highly regarded for technical expertise, rigorous compliance programs, and outstanding customer service - it is a current Good Manufacturing Practice (cGMP) facility in good standing with the US Food and Drug Administration (FDA).
The acquisition further advances Intertek's strategic growth in expert support services to the global pharmaceutical, medical device and drug delivery industry through the provision of state of the art analytical services.
CEO of Intertek's OCA Division (Caleb Brett), Mark Loughead, comments: "QTI has an outstanding reputation in the industry and will further expand our ability to support the pharmaceutical and related sectors for outsourced R&D and testing expertise."
John Conti-Ramsden, Ph.D., global director for Intertek Pharmaceutical Services, said: "The acquisition of QTI further develops Intertek's USA offering and global platform in the area of pharmaceutical services. Intertek already provides a wide range of testing services to pharmaceutical clients from its laboratories in Europe and Good Laboratory Practice (GLP) bio-analytical services from the Alta laboratories in California."
Paul Winslow, Ph.D., managing director of QTI comments: "Joining Intertek provides QTI a global network to access and serve the worldwide pharmaceutical industry. Additionally, Intertek's commitment to growth will allow QTI to expand our capabilities to provide a more comprehensive service offering to our key industry markets."
About Intertek Group plc
Intertek Group plc (LSE:ITRK) is a leading international provider of quality and safety services to a wide range of global and local industries. Partnership with Intertek brings increased value to customers’ products and processes, ultimately supporting their success in the global market place. Intertek has the experience, expertise, resources and global reach to support its customers through their network of 930 laboratories and offices, 18,000 people in 109 countries around the world. http://www.intertek.com
About Intertek Pharmaceutical Services:
Intertek’s Pharmaceutical and Speciality Chemical Laboratories provide a wide range of routine and non-routine laboratory testing services to support pharmaceutical, biotechnology and nanotechnology clients. A growing international network of Intertek laboratories and offices serve clients from a wide range of industries on a global basis with services including laboratory testing, outsourcing, inspection, R&D and process services. Intertek laboratories are ideally suited to support a diverse range of fine chemical, pharmaceutical and biotech activities.
QTI is a FDA and DEA registered contract Analytical Research & Development Laboratory, operating in accordance with cGMP regulations and associated guidance documents. Located in Whitehouse, NJ, QTI has been providing complete analytical solutions to the pharmaceutical and biotechnology communities since 1989. QTI’s mission is to exceed clients' expectations by providing innovative solutions for their analytical challenges and to help them achieve their technical business objectives while maintaining the highest level of quality assurance and regulatory compliance.
For more information, please click here
USA: Paul Winslow, Ph.D., +01-908-534-4445
Managing Director for QTI
UK: John Conti-Ramsden, Ph.D., +44 (0) 161-721-2236
Director Intertek Pharmaceutical Services
Intertek Pharmaceutical Services
USA: Erik Holladay, +01-713-407-3500
Global Marketing Director
Intertek OCA Division (Caleb Brett)
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
First Observation of Electronic Structure in Ag-Rh Alloy Nanoparticles Having Hydrogen Absorbing: Storage Property –Attempting to solve the mystery of why Ag-Rh alloy nanoparticles have a similar property to Pd– October 30th, 2014
Iranians Present Model to Predict Photocatalytic Process in Removal of Pollutants October 30th, 2014
Production of Biocompatible Polymers in Iran October 30th, 2014
Amorphous Coordination Polymer Particles as alternative to classical nanoplatforms for nanomedicine October 30th, 2014
PEN Inc. Chairman, Scott Rickert, Will Webcast a Live Company Update September 25, 1 PM EDT September 17th, 2014
State University of New York Trustees Unanimously Approve SUNY Polytechnic Institute (SUNY Poly) as New Name for Merged SUNY CNSE / SUNYIT September 9th, 2014
PEN Inc. Announces New Trading Symbol: PENC: Stock Continues Trading on the OTCQB September 3rd, 2014
Applied Nanotech Holdings, Inc. and NanoHoldings Inc. Complete Combination to Create PEN Inc.: New Company to Focus on Commercialization of Advanced Nanotechnology-Enabled Products; Scott Rickert Is Chairman and CEO September 2nd, 2014